{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-033892","form_type":"8-K","ticker":null,"cik":"0001603207","company_name":"Notable Labs, Ltd.","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.728216+00:00","generated_at":"2026-05-31T07:39:01.911186+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Notable Labs CEO Thomas Bock resigns; CSO Wagner named interim CEO","bullets":["Thomas Bock resigned as CEO and director effective Aug 26, 2024; no disagreement with company.","Joseph Wagner, CSO since 2020, appointed interim CEO; board initiates search for permanent CEO.","Bock retained as consultant for 3 years: $21,875/month year 1, $10,937/month years 2-3; option extension to 10th anniversary.","Wagner's annual base salary increased to $408k as of April 1, 2024; target bonus 30% of base.","Company reaffirms plan to initiate volasertib Phase 2 program in coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-033892","json":"https://secwatch.observer/filing/0001493152-24-033892.json","markdown":"https://secwatch.observer/filing/0001493152-24-033892.md","text":"https://secwatch.observer/filing/0001493152-24-033892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224033892/0001493152-24-033892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224033892/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:39:01.911186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"139ec9f0f0","claim":"Thomas A. Bock resigned as Chief Executive Officer at Notable Labs, Ltd..","evidence_excerpt":"On August 26, 2024, Dr. Thomas A. Bock resigned from his positions as Director and as Chief Executive Officer of Notable Labs, Ltd.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224033892/0001493152-24-033892-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c8054a5631","claim":"Joseph Wagner was appointed as Chief Executive Officer at Notable Labs, Ltd..","evidence_excerpt":"Simultaneously, on such date, Dr. Joseph Wagner, the Company’s Chief Scientific Officer, was also appointed as Chief Executive Officer on an interim basis while the Board of Directors completes a search for a new Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224033892/0001493152-24-033892-index.htm","confidence":0.98,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}